GlassScriptPhysician profile
Uzoamaka Flake
NPI 1184043523
$1,260.53
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $322 · 2021: $180 · 2022: $711 · 2023: $24.46 · 2024: $22.84.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $47.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $47.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $216.26 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $112.63 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $80.88 | 2022 | |
| Biogen, INC. | $80.83 | 2021-2022 | |
| Amneal Pharmaceuticals LLC | $69.04 | 2020-2022 | |
| Neurocrine Biosciences, INC. | $61.32 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $48.38 | 2022-2023 | |
| Lundbeck LLC | $47.35 | 2020-2022 | |
| Mdd US Operations, LLC | $43.23 | 2022-2024 | Gocovri |
| Livanova USA, INC. | $42.38 | 2020 | |
| Alexion Pharmaceuticals, INC. | $41.22 | 2020-2022 | |
| Genzyme Corporation | $38.72 | 2020 | |
| Jazz Pharmaceuticals INC. | $36.20 | 2022 | |
| Eisai INC. | $34.23 | 2020 | |
| Medtronic, INC. | $32.89 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $32.17 | 2020-2022 | |
| Amgen INC. | $30.84 | 2020-2022 | |
| Sk Life Science, INC. | $23.31 | 2022 | |
| Allergan, INC. | $21.85 | 2021 | |
| Avion Pharmaceuticals | $19.87 | 2022 | |
| Greenwich Biosciences, INC. | $19.01 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $17.90 | 2020 | |
| Emd Serono, INC. | $17.70 | 2020 | |
| Kyowa Kirin, INC. | $17.50 | 2020 | |
| Argenx US, INC. | $17.33 | 2022 | |
| Lilly USA, LLC | $15.46 | 2020 | |
| Grifols USA, LLC | $14.85 | 2020 | |
| Acorda Therapeutics, INC | $14.14 | 2020 | |
| Neurelis, INC. | $13.04 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Uzoamaka Flake listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.